US-based clinical-stage biotechnology company GlycoMimetics Inc plans to raise $100m by issuing shares of its common stock from time to time in a public offering.
The company plans to use funds for the production and clinical trials of its drug candidates and for general corporate purposes.
French biopharmaceutical company Erytech Pharma SA plans to raise $100m through an initial public offering of American Depositary Shares.
The company plans to use the funds for conducting Phase III clinical trials on eryaspase in the US and Europe, and other general corporate purposes.
ObsEva SA has issued seven million shares of its common stock and prepaid warrants priced at $8 a share in a private placement to raise $60m.
The French biopharmaceutical company plans to use the funds towards the research and development of its drug candidates.
US-based biopharmaceutical company Allena Pharmaceuticals Inc plans to issue shares of its common stock in an initial public offering (IPO) to raise $92m.
The company intends to use funds from the offering to carry out Phase trials of ALLN-177 and other general corporate purposes.
Spero Therapeutics Inc plans to raise $86.25m in an initial public offering (IPO) of shares of its common stock.
The US-based biopharmaceutical company plans to use the funds for the clinical trials of SPR994 and SPR994 and for working capital purposes.
